NCT06485674View on ClinicalTrials.gov

Long-Term Organ Damage: Anifrolumab Versus Real-World Standard of Care in Adult Patients With Active Systemic Lupus Erythematosus

CompletedOBSERVATIONAL
Enrollment

561

Participants

Timeline

Start Date

May 9, 2024

Primary Completion Date

June 24, 2025

Study Completion Date

June 24, 2025

Conditions
Long-Term Organ Damage in Adult Patients With Active Systemic Lupus Erythematosus
Trial Locations (1)

M5G 1L7

Research Site, Toronto

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

IQVIA Pvt. Ltd

INDUSTRY

collaborator

University Health Network, Toronto

OTHER

lead

AstraZeneca

INDUSTRY